S2Cbio

01/09/2022

신약개발 벤처회사 제뉴브와 CNS drug연구개발 계약을 했습니다. 아직 탐색단계이나 내년 상반기까지 GLP tox가 가능한 물질의 발굴이 목표입니다. 황송하게도 조선일보에 뉴스를 픽업해주었네요…

, ,

지뉴브-에스투시바이오, 세포 기반 AI 플랫폼 통한 퇴행성 뇌 질환 신약 개발 추진

01/12/2021

오늘 벤처인증을 받았습니다. 특별히 투자유치를 준비하는 것은 아니지만, 한발짝씩 앞으로 가는 것같습니다.

The certificate for S2Cbio as a venture company was granted yesterday. A small step but a big step for S2Cbio.

, #벤처인증

23/09/2019

S2Cbio와 일동제약이 항혈전치료 First-in-class 치료제 개발하기로 하였습니다. 저희가 발굴한 Validated target, hit compound를 기반으로 일봉의 Platform과 결합하여 3년이내에 후보물질을 개발하기로 하였습니다.
S2Cbio는 바이오텍생태계에 씨앗될 타겟, 선도물질을 발굴하여 Biotech 혹은 pharma와 같이 개발하여 서로의 가치를 상승시킬 목적으로 만들어진 NRDO입니다. 같이 일할 수 있는 기회가 많았으면 좋겠습니다.

, #일동제약,

일동제약은 23일 신약개발 벤처기업 ‘에스투시바이오’와 신개념 항혈전제 개발을 위한 공동연구 협약을 체결했다. 에스투시바이오는 자체 플랫폼과 원천기술을 활용해 신약 후보물질을 도…

23/09/2019

I post the history of S2Cbio for your information. Just in the L/I posting today...

10/08/2019

Yonsei University TLO and S2Bio agree a deal in August 12. S2Cbio will acquire the right on ANO6 and will exercise the screening technology and the information of the early hit for discovery of novel class of a drug.

18/07/2019

S2Cbio made CDA with JDBio for collaboration of GLP1RA and research contract for screening agonists of 5-HT receptor in May, 2019.

26/12/2018

Dr. KY Nam of Pharos I&BT visited S2Cbio today. Dr. Nam introduced the business plan and pipeline of Pharos, and we discussed the on-going projects of S2Cbio (PLDi, GLP1RA, PAR2 antagonist). Pharos will review today meeting and will arrange future meeting for the further discussion.

05/09/2018

Dr. Shin, CTO and Dr. Song, the director of planning of Whanin pharmaceutical company visited S2Cbio for future collaboration.

16/06/2018

S2CBio offers research collaboration to identify small-molecule hits of novel biological mechanism. Professor Han's group successfully identified novel PPI inhibitors of LRS and LagD interaction for modulation m-TOR pathway. (https://www.nature.com/articles/s41467-017-00785-0)
Now the detail mechanism of this small molecule in PNAS online.(http://www.pnas.org/content/early/2018/05/18/1801287115.short)

Leucyl-tRNA synthetase (LRS) is a leucine sensor of the mTORC1 pathway. Here, the authors identify inhibitors of the GTPase activating function of LRS, not affecting its catalytic activity, and demonstrate that the leucine sensor function of LRS can be a new target for mTORC1 inhibition.

20/05/2018

S2CBio for contracted research. We offer screening method development, HTS, HCS and FBDD for lead discovery. S2CBio was founded by professors G. Han and W. Namkung of Yonsei University. S2CBio also has a couple of products in discovery pipeline: PLDi, GLP1RA and PAR2 RA.